Tenaya Therapeutics (TNYA) Payables (2020 - 2026)

Tenaya Therapeutics' Payables history runs 7 years deep, the most recent figure standing at $1.9 million for Q1 2026.

• On a quarterly basis, Payables fell 62.2% year-over-year to $1.9 million in Q1 2026; TTM through Mar 2026 was $1.9 million, a 62.2% decrease from a year earlier, with the FY2025 full-year figure at $3.6 million, down 30.63% from the prior year.
• Payables slipped to $1.9 million in Q1 2026 per TNYA's latest filing, from $3.6 million in the prior quarter.
• Across five years, Payables topped out at $9.6 million in Q4 2022 and bottomed at $1.9 million in Q1 2026.
• The 5-year median for Payables is $5.3 million (2022), against an average of $5.6 million.
• Across the five-year window, Payables jumped 58.67% in 2023 and sank 62.2% in 2026, its largest moves.
• Year by year, Payables stood at $9.6 million in 2022, then slumped by 41.22% to $5.6 million in 2023, then retreated by 8.31% to $5.2 million in 2024, then slumped by 30.63% to $3.6 million in 2025, then slumped by 46.55% to $1.9 million in 2026.
• Per Business Quant, the three latest TNYA Payables figures stand at $1.9 million (Q1 2026), $3.6 million (Q4 2025), and $2.8 million (Q3 2025).